XW 10172

Drug Profile

XW 10172

Alternative Names: XW-10172

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XW labs
  • Class Neuroprotectants; Sleep disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Narcolepsy

Most Recent Events

  • 22 Jun 2018 XW Laboratories plans a phase I XW10172-101 trial for Narcolepsy (In volunteers) in Australia (PO) in August 2018 (ACTRN12618001038280p)
  • 12 Mar 2018 Phase-I clinical trials in Narcolepsy (In volunteers) in Australia (PO) (ACTRN12618000127202)
  • 02 Feb 2018 Preclinical trials in Narcolepsy in China (PO) before February 2018 (ACTRN12618000127202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top